50 mg/mL (per mL): $7.56 - $33.

70

100 mg/mL (per mL): $15.12 - $61.78

Solution (Haloperidol Lactate Injection)

5 mg/mL (per mL): $0.48 - $7.37

Tablets (Haloperidol Oral)

0.5 mg (per each): $0.33 - $0.89

1 mg (per each): $0.46 - $1.07

2 mg (per each): $0.63 - $1.25

5 mg (per each): $0.91 - $1.09

10 mg (per each): $1.38 - $2.01

20 mg (per each): $2.76 - $3.62

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as
reference price only. A range is provided when more than one manufacturer's AWP price is
available and uses the low and high price reported by the manufacturers to determine the
range. The pricing data should be used for benchmarking purposes only, and as such should
not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or
considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly
disclaims all warranties of any kind or nature, whether express or implied, and assumes no
liability with respect to accuracy of price or price range data published in its solutions. In no
event shall Medi-Span be liable for special, indirect, incidental, or consequential damages
arising from use of price or price range data. Pricing data is updated monthly.

Brand Names: International

Aloperidin (GR);
Avant (MT);
Decadol (PL);
Galopril (UA);
Haldol (AT, BB, BZ, CL, CY, DE, EG, GB,
HR, IE, IS, JO, KW, LB, LU, MT, MX, NI, NO, NZ, PA, PE, PH, PK, PT, RO, SA, SE, SI, TR, VE);
Haldol
Decanoas (AE, BE, BF, BG, BJ, BM, BS, CH, CI, CR, CY, CZ, DO, EC, EG, ET, FR, GH, GM, GN, GT, GY,
HK, HN, ID, IL, IQ, IR, IT, JM, JO, KE, KR, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NL, OM, PR,
PY, SA, SC, SD, SL, SN, SR, SV, SY, TN, TT, TW, TZ, UG, UY, YE, ZM, ZW);
Haldol decanoas (LU);
Haldol Decanoate (AU, BB);
Haldol Decanoato (BR, CL);
Haldol depo (HR);
Haldol Depot (NO);
Halonace (EG);
Halop (BD);
Haloper (DE, HK, RU);
Haloperidol Decanoat (HU);
Haloperidol Esteve
(ES);
Haloperidol Prodes (ES);
Haloperidol-ratiopharm (LU);
Haloperil (CR, DO, GT, HN, MX, NI,
PA, SV);
Halopidol decanoato (AR, CO);
Haloslip (LK);
Haloxen (SG);
Haridol Decanoate (TH);
Haridol-D (CN);
Hazidol (VN);
Holt (BD);
Manace (MY);
Mapress (MY);
Motivan (SG);
Norodol (TR);
Peldol (BD);
Pericate (IL);
Peridol (BD, EG);
Perol (BD);
Psyqure (PH);
Senorm L.A. (IN);
Seranace
(GB, IE, ZA);
Seredol Deca (PH);
Serenace (AE, CY, GB, JP, LK, MT, PH, SA, SG, TR);
Serenase (FI);
Serenase Dekanoat (DK);
Starhal (VN);
Sutran X (PY);
Zocalm-5 (LK);
Zuredel (PH)

For country abbreviations used in Lexicomp ( show table)

Use of UpToDate is subject to the Subscription and License Agreement.

REFERENCES

1. 2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 Updated
AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67(4):674-
694. doi: 10.1111/jgs.15767. [PubMed 30693946]

2. Abidi S, Mian I, Garcia-Ortega I, et al. Canadian guidelines for the pharmacological treatment of schizophrenia
spectrum and other psychotic disorders in children and youth. Can J Psychiatry. 2017;62(9):635-647.
doi:10.1177/0706743717720197 [PubMed 28764561]

3. ACOG Committee on Practice Bulletins-Obstetrics, "ACOG Practice Bulletin: Clinical Management Guidelines for
Obstetrician-Gynecologists Number 92, April 2008 (Replaces Practice Bulletin Number 87, November 2007). Use of
Psychiatric Medications During Pregnancy and Lactation," Obstet Gynecol, 2008, 111(4):1001-20. [PubMed
18378767]

4. Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested
and rejected. Arch Gen Psychiatry. 2003;60(12):1228-1235. doi:10.1001/archpsyc.60.12.1228 [PubMed 14662555]

5. Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed
11487763]

6. Alonso-Pedrero L, Bes-Rastrollo M, Marti A. Effects of antidepressant and antipsychotic use on weight gain: a
systematic review. Obes Rev. 2019;20(12):1680-1690. doi:10.1111/obr.12934 [PubMed 31524318]

7. Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. Curr Drug Saf.
2010;5(1):97-104. doi:10.2174/157488610789869265 [PubMed 20210726]

8. American Diabetes Association; American Psychiatric Association; American Association of Clinical

Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on
antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65(2):267-272. [PubMed 15003083]

9. Annamalai A, Kosir U, Tek C. Prevalence of obesity and diabetes in patients with schizophrenia. World J Diabetes.
2017;8(8):390-396. doi:10.4239/wjd.v8.i8.390 [PubMed 28861176]

10. Anzai T, Takahashi K, Watanabe M. Adverse reaction reports of neuroleptic malignant syndrome induced by
atypical antipsychotic agents in the Japanese Adverse Drug Event Report (JADER) database. Psychiatry Clin
Neurosci. 2019;73(1):27-33. doi:10.1111/pcn.12793 [PubMed 30375086]
11. Arakawa R, Okumura M, Ito H, et al. Positron emission tomography measurement of dopamine D₂ receptor
occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. J Clin
Psychiatry. 2010;71(9):1131-1137. doi:10.4088/JCP.08m04307yel [PubMed 20361897]

12. Bach DS, Rybak MJ. Haloperidol-associated hyperthermia. Drug Intell Clin Pharm. 1985;19(3):211.
doi:10.1177/106002808501900313 [PubMed 3979264]

13. Balai M, Ansari F, Gupta LK, Khare AK, Mittal AK. Urticaria and angioedema associated with haloperidol. Indian J
Dermatol. 2017;62(5):539-540. doi:10.4103/ijd.IJD_257_17 [PubMed 28979025]

14. Ballard C, Hanney ML, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term
follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009;8(2):151-157. doi:10.1016/S1474-
4422(08)70295-3 [PubMed 19138567]

15. Balon R, Berchou R, Zethelius M. Thrombocytopenia associated with chlorpromazine, haloperidol and thiothixene:
a case report. Can J Psychiatry. 1987;32(2):149-150. doi:10.1177/070674378703200213 [PubMed 3567823]

16. Bark N. Deaths of psychiatric patients during heat waves. Psychiatr Serv. 1998;49(8):1088-1090.
doi:10.1176/ps.49.8.1088 [PubMed 9712220]

17. Basch E, Prestrud AA, Hesketh PJ, et al; American Society of Clinical Oncology. Antiemetics: American Society of
Clinical Oncology clinical practice guideline update [published correction appears in J Clin Oncol.
2014;32(19):2117]. J Clin Oncol. 2011;29(31):4189-4198. [PubMed 21947834]

18. Baweja R, Sedky K, Lippmann S. Long-acting antipsychotic medications. Curr Drug Targets. 2012;13(4):555-560.
[PubMed 22250654]

19. Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC. QTc prolongation, torsades de pointes, and
psychotropic medications. Psychosomatics. 2013;54(1):1-13. doi:10.1016/j.psym.2012.11.001 [PubMed 23295003]

20. Beach SR, Celano CM, Sugrue AM, et al. QT Prolongation, torsades de pointes, and psychotropic medications: a 5-
year update. Psychosomatics. 2018;59(2):105-122. doi:10.1016/j.psym.2017.10.009 [PubMed 29275963]

21. Bellamy CJ, Kane-Gill SL, Falcione BA, Seybert AL. Neuroleptic malignant syndrome in traumatic brain injury
patients treated with haloperidol. J Trauma. 2009;66(3):954-958. doi:10.1097/TA.0b013e31818e90ed [PubMed
19276778]

22. Belvederi Murri M, Guaglianone A, Bugliani M, et al. Second-generation antipsychotics and neuroleptic malignant
syndrome: systematic review and case report analysis. Drugs R D. 2015;15(1):45-62. doi:10.1007/s40268-014-
0078-0 [PubMed 25578944]

23. Berman BD. Neuroleptic malignant syndrome: a review for neurohospitalists. Neurohospitalist. 2011;1(1):41-47.
doi:10.1177/1941875210386491 [PubMed 23983836]

24. Bhuvaneswar CG, Baldessarini RJ, Harsh VL, Alpert JE. Adverse endocrine and metabolic effects of psychotropic
drugs: selective clinical review. CNS Drugs. 2009;23(12):1003-1021. doi:10.2165/11530020-000000000-00000
[PubMed 19958039]

25. Bloechliger M, Rüegg S, Jick SS, Meier CR, Bodmer M. Antipsychotic drug use and the risk of seizures: follow-up
study with a nested case-control analysis. CNS Drugs. 2015;29(7):591-603. doi:10.1007/s40263-015-0262-y
[PubMed 26242478]
26. Bobes J, Garc A-Portilla MP, Rejas J, et al. Frequency of sexual dysfunction and other reproductive side-effects in
patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the
EIRE study. J Sex Marital Ther. 2003;29(2):125-147. doi:10.1080/713847170 [PubMed 12623765]

27. Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic-induced hyperprolactinemia. Pharmacotherapy.
2009;29(1):64-73. doi:10.1592/phco.29.1.64 [PubMed 19113797]

28. Bouchama A, Dehbi M, Mohamed G, Matthies F, Shoukri M, Menne B. Prognostic factors in heat wave related
deaths: a meta-analysis. Arch Intern Med. 2007;167(20):2170-2176. doi:10.1001/archinte.167.20.ira70009
[PubMed 17698676]

29. Brown RL, Henke A, Greenhalgh DG, Warden GD. The use of haloperidol in the agitated, critically ill pediatric
patient with burns. J Burn Care Rehabil. 1996;17(1):34-38. [PubMed 8808357]

30. Burbuqe I, Boettger S, Schubert M, Bettex D, Rudiger A. QTc prolongation after haloperidol administration in
critically ill patients post cardiovascular surgery: a cohort study and review of the literature. Palliat Support Care.
2020;18(4):447-459. doi:10.1017/S1478951520000231 [PubMed 32345400]

31. Büttner M, Walder B, von Elm E, Tramèr MR. Is low-dose haloperidol a useful antiemetic?: A meta-analysis of
published and unpublished randomized trials. Anesthesiology. 2004;101(6):1454-1463. [PubMed 15564955]

32. Canadian Psychiatric Association (CPA). Clinical practice guidelines. Treatment of schizophrenia. Can J Psychiatry.
2005;50(13)(suppl 1):7S-57S. [PubMed 16529334]

33. Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation
antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78(3):e264-e278. doi:10.4088/JCP.16r10832 [PubMed
28146614]

34. Carlson CD, Cavazzoni PA, Berg PH, Wei H, Beasley CM, Kane JM. An integrated analysis of acute treatment-
emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons
with placebo, haloperidol, risperidone, or clozapine. J Clin Psychiatry. 2003;64(8):898-906.
doi:10.4088/jcp.v64n0807 [PubMed 12927004]

35. Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of
the CATIE schizophrenia trial. Neurol Clin. 2011;29(1):127-viii. doi:10.1016/j.ncl.2010.10.002 [PubMed 21172575]

36. Castro E, Körver F, Merry A, et al. Should we still monitor QTc duration in frail older patients on low-dose
haloperidol? A prospective observational cohort study. Age Ageing. 2020;49(5):829-836.
doi:10.1093/ageing/afaa066 [PubMed 32614955]

37. Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR
Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm
[PubMed 6810084]

38. Cerovecki A, Musil R, Klimke A, et al. Withdrawal symptoms and rebound syndromes associated with switching
and discontinuing atypical antipsychotics: theoretical background and practical recommendations. CNS Drugs.
2013;27(7):545-572. doi: 10.1007/s40263-013-0079-5. [PubMed 23821039]

39. Chen JJ. Drug-induced movement disorders. Mental Health Clinician. 2012;1(7):167-173. doi: 10.9740/mhc.n90206
40. Christodoulou C, Kalaitzi C. Antipsychotic drug-induced acute laryngeal dystonia: two case reports and a mini
review. J Psychopharmacol. 2005;19(3):307-311. doi:10.1177/0269881105051543 [PubMed 15888517]
41. Cipriani A, Rendell JM, Geddes JR. Haloperidol alone or in combination for acute mania. Cochrane Database Syst
Rev. 2006;(3)CD004362. [PubMed 16856043]

42. Clinton JE, Sterner S, Stelmachers Z, Ruiz E. Haloperidol for sedation of disruptive emergency patients. Ann Emerg
Med. 1987;16(3):319-322. [PubMed 3813167]

43. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics:
a systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):414-425. doi:10.1176/appi.ajp.161.3.414
[PubMed 14992963]

44. Corripio I, Ferreira A, Portella MJ, et al. The role of striatal dopamine D2 receptors in the occurrence of
extrapyramidal side effects: iodine-123-iodobenzamide single photon emission computed tomography study.
Psychiatry Res. 2012;201(1):73-77. doi:10.1016/j.pscychresns.2011.02.004 [PubMed 22281201]

45. Couto J, Dos Santos LP, Mendes T, López R. Life-threatening hypoglycemia attributable to haloperidol in a patient
with schizophrenia. Braz J Psychiatry. 2019;41(2):190-191. doi:10.1590/1516-4446-2018-0356 [PubMed 30942323]

46. Cox JH, Seri S, Cavanna AE. Clinical guidelines on long-term pharmacotherapy for bipolar disorder in children and
adolescents. J Clin Med. 2014;3(1):135-143. doi:10.3390/jcm3010135 [PubMed 26237252]

47. Crawford AM, Beasley CM Jr, Tollefson GD. The acute and long-term effect of olanzapine compared with placebo
and haloperidol on serum prolactin concentrations. Schizophr Res. 1997;26(1):41-54. doi:10.1016/S0920-
9964(97)00036-4 [PubMed 9376336]

48. Crouse EL, Alastanos JN, Bozymski KM, Toscano RA. Dysphagia with second-generation antipsychotics: a case
report and review of the literature. Ment Health Clin. 2018;7(2):56-64. doi:10.9740/mhc.2017.03.056 [PubMed
29955499]

49. Cruz FG, Thiagarajan D, Harney JH. Neuroleptic malignant syndrome after haloperidol therapy. South Med J.
1983;76(5):684-686. doi:10.1097/00007611-198305000-00044 [PubMed 6844982]

50. Cutler NR, Heiser JF. Leukopenia following treatment with thiothixene and haloperidol. JAMA. 1979;242(26):2872-
2873. [PubMed 513257]

51. D’Angelo RG, Rincavage M, Tata AL, et al. Impact of an antipsychotic discontinuation bundle during transitions of
care in critically ill patients. J Intensive Care Med. 2019;34(1):40-47. doi: 10.1177/0885066616686741. [PubMed
28049388]

52. Darby JK, Pasta DJ, Dabiri L, Clark L, Mosbacher D. Haloperidol dose and blood level variability: toxicity and
interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. J Clin
Psychopharmacol. 1995;15(5):334-340. [PubMed 8830064]

53. David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma
prolactin levels in patients with schizophrenia. Clin Ther. 2000;22(9):1085-1096. doi:10.1016/S0149-
2918(00)80086-7 [PubMed 11048906]

54. Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated

weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat.
2017;13:2231-2241. doi:10.2147/NDT.S113099 [PubMed 28883731]